Kintor Pharmaceutical : Pharma Roadshow Presentation

Kintor Pharma

A Global Leader in the Research, Development and Commercialisation of Innovative Therapies

Confidential

Milestones Reached in H12022

R&D Moves Steadily

Innovative FIC/BIC Drug Candidates in PI-III Clinical Stage

Pipelines in Registritional PIII Clinical Stage2

Pipelines ongoing outside China3

Academic Publications4

Positive Data Release

• Data of US & Intl Outpatient Phase III Study- GT0918
• • Reduce of Hospitalization/mortality
  • Clearance of COVID-19 virus
  • COVID-19related symptoms improvement
• Data of Male AGA PII in China-KX-826
• • Good Safety
  • Increased 15.34 hairs/cm2 compared with placebo group(P=0.024)

	Governmental Specific Funds Support			Capital Market Recognized
	National and Principal Specific Funds Support received				Included in MSCI China Index in 2022H1，added to its
			inclusion to Hang Seng Composite Index(2021),
	from Chinese Government			Southbound Stock Connect and FTSE Russell Global
					Equity Index(2020)

Note：1. FIC/BIC: First-in-class/Best-in-class. 2. COVID-19 pipeline NCT04870606 and mCRPC pipeline CTR20180849 were excluded.

3. 6 pipelines of 5 drug candidates are developing out of China(including HK/TW/Macao)； 4. COVID-19 pipeline data&Mechanism, AGA and c-Myc pipelines

1

Table of Content

01	Company Overview
02	Introduction of Candidates in Clinical Stage
03	Our Strategies
04	Financial Overview
05	Appendix

2

Section 1

Company Overview

Kintor at a Glance - in China for Global

2009

Oncology & AR-Focused1

7+N Pipeline

Established as Suzhou Kintor	Focused on oncology AR-related diseases
by Dr. Tong and Dr. Guo	with substantial unmet medical needs

Small molecule & biological drugs: 7 potential first/best-in-class in clinical, N in pre-clinical

Indications	Geographic Expansion
COVID-19, fastest growing cancers (prostate,	Potentially leveraging our global relationships
breast & liver) globally, and other AR-related	to license-out select products for rapid global
indications like AGA2 and acne vulgaris	expansion in the future

Pruxelutamide (GT0918)3	Pyrilutamide (KX-826)	ALK-1 antibody (GT90001)
Our lead product, indications in COVID-19,	Indications in androgenetic alopecia and acne	A new anti-angiogenesis inhibitor, positive
prostate cancer, and breast cancer	vulgaris, phase II trial in China for AGA met	data of HCC phase II trial in Taiwan,
	primary endpoints, and phase III is ongoing	conducting trials in China and US

Note:

1 AR refers to androgen receptor 2. AGA: androgenetic alopecia; 3. "Pruxelutamide" is previously known as "Proxalutamide"

4